e.g., HRA000087; HRA000150
HRA003964
Title:
KK-LC-1 represents a feasible therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer
Release date:
2023-03-31
Description:
One of the objectives of this study was to explore the differential expression genes in triple-negative breast cancer after resistance to docetaxel.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Cell line related study
Disease name:
triple-receptor negative breast cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
CSC&TM DAC
Contact person:
Liu Caigang
Email:
liucg@sj-hospital.org
Description:
Our Data Access Communitee consists of two members whose main responsibilities are to oversee and supervise the work of the Data Governance Office and to adjudicate interdepartmental coordination issues that may arise in the data governance process and that the Data Governance Office cannot resolve.
Individuals & samples
Individual Accession
Individual Name
Gender
Sample Accession
Sample Name
Sample Description
Individual Accession
Individual Name
Gender
Sample Accession
Sample Name
Sample Description
HRI368779MDA-MB-231/WT1femaleHRS554971WT1wild type
HRI368780MDA-MB-231/WT2femaleHRS554972WT2wild type
HRI368781MDA-MB-231/WT3femaleHRS554973WT3wild type
HRI368782MDA-MB-231/TAXre1femaleHRS554974TAXre1TAX resistance
HRI368783MDA-MB-231/TAXre2femaleHRS554975TAXre2TAX resistance
HRI368784MDA-MB-231/TAXre3femaleHRS554976TAXre3TAX resistance
Showing 1 to 6 of 6 rows rows per page
Run accession
Files
Experiment
Experiment title
Platform
Sample
Run accession
Files
Experiment
Experiment title
Platform
Sample
HRR913105HRR913105_f1.fq.gz (1.54 GB)HRX664482control group 1Illumina NovaSeq 6000HRS554971 (SAMC2558469)
HRR913105HRR913105_r2.fq.gz (1.65 GB)HRX664482control group 1Illumina NovaSeq 6000HRS554971 (SAMC2558469)
HRR913106HRR913106_f1.fq.gz (1.53 GB)HRX664483control group 2Illumina NovaSeq 6000HRS554972 (SAMC2558473)
HRR913106HRR913106_r2.fq.gz (1.66 GB)HRX664483control group 2Illumina NovaSeq 6000HRS554972 (SAMC2558473)
HRR913107HRR913107_f1.fq.gz (1.53 GB)HRX664484control group 3Illumina NovaSeq 6000HRS554973 (SAMC2558475)
HRR913107HRR913107_r2.fq.gz (1.65 GB)HRX664484control group 3Illumina NovaSeq 6000HRS554973 (SAMC2558475)
HRR913108HRR913108_f1.fq.gz (1.54 GB)HRX664485TAX resistance group 1Illumina NovaSeq 6000HRS554974 (SAMC2558481)
HRR913108HRR913108_r2.fq.gz (1.67 GB)HRX664485TAX resistance group 1Illumina NovaSeq 6000HRS554974 (SAMC2558481)
HRR913109HRR913109_f1.fq.gz (1.67 GB)HRX664486TAX resistance group 2Illumina NovaSeq 6000HRS554975 (SAMC2558487)
HRR913109HRR913109_r2.fq.gz (1.79 GB)HRX664486TAX resistance group 2Illumina NovaSeq 6000HRS554975 (SAMC2558487)
Showing 1 to 10 of 12 rows rows per page
Submitter:   Liu Caigang / liucg@sj-hospital.org
Organization:   Shengjing Hospital of China Medical University
Submission date:   2023-02-15
Requests:   3